RetiSpec
RetiSpec is a Toronto-based medical imaging startup developing an AI-driven hyperspectral retinal imaging platform for non-invasive, early detection of Alzheimer's disease pathology, targeting eye care clinics, memory clinics, and pharmaceutical clinical trial screening.
- Company typePrivate
- Founded2016
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What RetiSpec does
RetiSpec is a Toronto-based medical imaging company developing an AI-driven, point-of-care diagnostic for the early detection of Alzheimer's disease pathology through hyperspectral retinal imaging. Its core product analyzes retinal images captured with existing eye-clinic cameras, extracting more than 100 spectral bands per pixel (versus the three bands in standard RGB imaging) to detect amyloid beta biomarkers via proprietary AI algorithms developed from technology licensed from the University of Minnesota's Center for Drug Design. The platform is positioned as a non-invasive, affordable alternative to PET-based and CSF-based Alzheimer's diagnostics, with the goal of identifying disease years before clinical symptom onset.
The company's go-to-market targets three primary customer segments: eye care providers and clinics (optometrists and ophthalmologists) as the primary channel for routine screening; memory clinics and neurology practices for point-of-care evaluation of at-risk patients; and pharmaceutical/biotech companies using the retinal test to pre-screen participants for Alzheimer's clinical trials, improving recruitment efficiency. RetiSpec entered a strategic collaboration and investment agreement with Topcon Healthcare in April 2024 and closed a $10M USD funding round in July 2024 to advance commercialization, alongside partnerships with VSP Vision, the Global Alzheimer's Platform Foundation, and the Alzheimer's Drug Discovery Foundation.
RetiSpec is currently pre-revenue: its technology is explicitly designated for research use only and is not yet FDA-cleared or commercially available. The business model anticipates recurring revenue via deployment through existing retinal imaging infrastructure in eye clinics, with the ~24-person team structured around AI engineering, clinical operations, regulatory affairs, and business development to support the transition from research validation to commercial launch.
RetiSpec firmographics
Firmographics- Name
- RetiSpec
- Legal name
- RetiSpec Inc.
- Website
- https://retispec.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RetiSpec is a Toronto-based medical imaging startup developing an AI-driven hyperspectral retinal imaging platform for non-invasive, early detection of Alzheimer's disease pathology, targeting eye care clinics, memory clinics, and pharmaceutical clinical trial screening.
- Ownership category
- akta.pro rank
RetiSpec industry classification
Industry- Product category
- Medical Imaging Diagnostics
- NAICS
- Diagnostic Imaging Centers (621512)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where RetiSpec is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
RetiSpec business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Pre-revenue / Research Use Only: RetiSpec's technology is currently for research use only and not yet commercially available. The company closed $10M USD in July 2024 to advance commercialization of its AI-driven eye test for detection of Alzheimer's disease, indicating they are in pre-commercialization stage.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
RetiSpec product offering
Product offeringCore offering
RetiSpec develops an AI-driven diagnostic platform that uses hyperspectral retinal imaging to detect Alzheimer's disease pathology (amyloid beta) years before clinical symptoms emerge. The platform analyzes data from existing retinal imaging cameras already deployed in eye clinics, combining hyperspectral image capture with explainable AI algorithms to deliver non-invasive, point-of-care screening for neurodegenerative disease markers.
Product overview
RetiSpec offers a unified AI-driven diagnostic platform for early Alzheimer's disease detection through retinal imaging. The core offering combines the RetiSpec Hyperspectral Retinal Imaging System (a medical device that captures multi-spectral retinal images) with the RetiSpec AI-Based Retinal Test (software that analyzes these images to detect amyloid beta biomarkers). The solution uses existing retinal imaging cameras found in eye clinics, enhanced with hyperspectral imaging technology and explainable AI algorithms to enable non-invasive early detection of Alzheimer's disease.
Differentiator
Problem solved
Functional benefit
Products and services
- RetiSpec AI-Based Retinal Test
Quantifiable outcome
- RetiSpec's retinal scan demonstrated comparable performance to blood-based biomarkers for predicting brain Aβ pathology in Bio-Hermes-001 study
- +2 more outcomes
Companies that use RetiSpec
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
RetiSpec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
RetiSpec partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor, core and major.
- VSP VisionminorRetiSpec was spotlighted by Techonomy in partnership with VSP Vision as one of ten AI and Health Access innovators using technology to expand healthcare access to underserved populations.
- Topcon Healthcare, Inc.coreTopcon Healthcare announced collaboration and investment with RetiSpec to help bring the eye-based AI diagnostic tool to market. This partnership combines Topcon's expertise in eye care technology with RetiSpec's AI capabilities to accelerate commercialization of the Alzheimer's detection solution.
- University of Minnesota's Center for Drug DesigncoreRetiSpec's solution draws on technology developed by Robert Vince, Ph.D., and Swati More, Ph.D., at the University of Minnesota's Center for Drug Design. Professor Vince, inventor of abacavir (Ziagen), and Professor More developed the underlying method of using retinal hyperspectral imaging to detect Alzheimer's disease pathology.
- Global Alzheimer's Platform Foundation (GAP)majorJohn Dwyer, Co-Founder and President of GAP, has publicly endorsed RetiSpec's technology. RetiSpec's test results are included in the Bio-Hermes database along with brain amyloid PET scan results to advance understanding of retinal imaging's role in Alzheimer's.
- Alzheimer's Drug Discovery FoundationmajorDr. Howard Fillit, MD, Executive Director and CSO of the Alzheimer's Drug Discovery Foundation, has provided endorsement of RetiSpec's retinal scanner as a unique diagnostic tool with potential to facilitate early diagnosis and improve patient lives.
- Toronto Memory ProgrammajorDr. Sharon Cohen, Medical Director and Behavioural Neurologist at Toronto Memory Program, has provided endorsement of RetiSpec's technology. Toronto Memory Program and RetiSpec were featured together as a case study on the Davos Alzheimer's Collaborative Blueprint.
Scale indicators3 records
Recent moves6 records
Expansion highlights7 records
RetiSpec competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: C2N Diagnostics offers the PrecivityAD blood-based test for Alzheimer's amyloid detection, directly competing with RetiSpec in the early Alzheimer's diagnostic space. Both target non-invasive, scalable alternatives to PET imaging, though C2N uses plasma biomarkers rather than retinal imaging.
- Quanterix: Quanterix develops ultra-sensitive blood-based biomarker assays for neurodegenerative diseases including Alzheimer's. Both RetiSpec and Quanterix compete in enabling earlier, less invasive detection of Alzheimer's pathology, though via different biological matrices (retina vs. plasma).
- iHealthScreen: iHealthScreen applies AI to retinal images for risk prediction of systemic and neurodegenerative conditions. Both companies share the AI-retinal-imaging approach to non-invasive disease screening and target eye-care providers as the deployment channel.
- Notal Vision: Notal Vision provides AI-driven home-based retinal monitoring (ForeseeHome) and clinic-based diagnostic imaging services. Both companies apply AI to retinal imaging for disease management and target ophthalmology clinic workflows.
Broad incumbents
- Topcon Healthcare: Topcon Healthcare is a global ophthalmic device manufacturer and RetiSpec's strategic partner. As a broad incumbent in retinal imaging hardware, Topcon both enables RetiSpec's distribution and represents a strategic risk if it chooses to internalize competing AI capabilities.
- Optos (Nikon): Optos manufactures ultra-widefield retinal imaging devices used in eye clinics globally. RetiSpec's solution operates on retinal cameras including those from Optos, making Optos a channel partner and a potential competitor if it bundles its own AI diagnostic offerings.
- icometrix: icometrix develops AI-based analysis of brain MRI/CT scans for neurological conditions including multiple sclerosis and dementia. Both companies apply AI imaging diagnostics to neurodegenerative disease, although icometrix focuses on brain imaging rather than retinal.
Emerging players
- Linus Health: Linus Health offers digital cognitive assessment tools for early detection of cognitive impairment and Alzheimer's. Both companies pursue earlier, accessible detection of neurodegenerative decline, but Linus uses digital pen-and-tablet cognitive tests rather than retinal biomarkers.
- Spectral MD: Spectral MD applies hyperspectral imaging and AI for wound care diagnostics. While the application area differs, the underlying hyperspectral imaging + AI architecture is technically analogous to RetiSpec's approach, making it a relevant technology peer.
- ADx NeuroSciences: ADx NeuroSciences develops biomarker assays (CSF and blood) for Alzheimer's and other neurodegenerative diseases. Both companies are advancing biomarker-based diagnostics for early Alzheimer's detection, though ADx focuses on biofluid assays rather than retinal imaging.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
RetiSpec social profiles
Digital presenceRetiSpec financial estimates
Financial estimateRevenue estimate
Valuation estimate
RetiSpec leadership team
Management profileNumber of profiles
Profiles8 records
RetiSpec funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RetiSpec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RetiSpec
What does RetiSpec do?
RetiSpec develops an AI-driven diagnostic platform that uses hyperspectral retinal imaging to detect Alzheimer's disease pathology (amyloid beta) years before clinical symptoms emerge. The platform analyzes data from existing retinal imaging cameras already deployed in eye clinics, combining hyperspectral image capture with explainable AI algorithms to deliver non-invasive, point-of-care screening for neurodegenerative disease markers.
Is RetiSpec a public or private company?
RetiSpec is a private company. It is classified as venture growth investor backed and is currently operating.
When was RetiSpec founded?
RetiSpec was founded in 2016. It employs 11 to 50 people.
Where is RetiSpec based?
RetiSpec is headquartered in Toronto, Canada, in the North America region.
How does RetiSpec make money?
One revenue line is on record: pre-revenue / Research Use Only.
Who are RetiSpec's main competitors?
Direct peers on record are C2N Diagnostics, Quanterix, iHealthScreen and Notal Vision. Broad incumbents are Topcon Healthcare, Optos (Nikon) and icometrix. Emerging players are Linus Health, Spectral MD and ADx NeuroSciences.
Does RetiSpec have an API?
No public API is recorded for RetiSpec.
What industry is RetiSpec in?
RetiSpec's product category is Medical Imaging Diagnostics. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 621512.